A decade inside the regulatory and clinical work behind CE and FDA — written into the earliest checks.
Class II and above hardware where the regulatory pathway and clinical evidence are the moat.
SaMD and AI/ML in medicine. Where risk classification is real and QMS discipline is real.
IVDR-adjacent diagnostics and instruments used in the lab and the clinic. Not therapeutics.
Personal capital. Angel checks. One-page decisions. No fund, no committee, no term-sheet theatre.
When time and hands-on expertise are the more useful contribution than capital, we may propose sweat equity in place of — or alongside — a cheque. Allocated hours in regulatory pathway, clinical evidence, notified-body prep, and RA/QA hiring, exchanged for a small equity position on standard terms.
Most suited for very early stage
We come in at the point where the regulatory pathway and clinical evidence plan are being drafted. An operator with reps compresses six months of learning into a two-hour whiteboard.
Nordic and European founders sit inside our network and timezone. The current book spans Denmark, New Zealand, and the United States.
We follow standard terms of the round. We don't lead process on terms unless we're leading the round. No board seats at first check.
Regulatory pathway review · clinical evidence plan · CE/FDA narrative · first RA/QA hire calls · introductions to notified bodies and follow-on capital. Priced into the check.
A family of tools that help MedTech and BioTech companies build and certify their medical devices — regulatory and clinical documentation, CERs, PMS/PSUR, MDR workflows.
→Building for one of neurology's most under-served indications — cluster headache — from Copenhagen.
→Sleep-medicine hardware — a CPAP company out of New Zealand, in a category the incumbents haven't rethought in a decade.
website in progressThe first robotic brain scanner built for chiropractic — real-time EEG and HRV visualised during patient adjustments. Brain health, made visible.
→Medicine's hardest work happens at the start. Regulatory pathway, clinical evidence, the first RA/QA hire — decisions in the earliest stretch that determine whether a device ever reaches a patient.
MTLS Group exists for that stretch. Personal capital, or operating time on the tools, for MedTech, SaMD, and diagnostics founders who take the standards — and the timelines — seriously.
Small book by design. Behind the vehicle: Morten Togo Sørensen, MD — a decade of regulatory and clinical work sits behind every check.
First meeting to yes-or-no in fourteen days. If we can't get there, we say so on day one. Most nos come with a reason and, where possible, a next introduction.
Rarely. We're built to be the second or third call, not the first. When we lead, it's a small angel round with founders we already know.
Not at first check. If the position grows and the founder wants one, we consider it — with a clear scope and a clear end.
MTLS Group is the investment vehicle. Medflow is a separate operating company held as a portfolio position. The two brands are legally and visually distinct — MTLS Group does not build product, and Medflow is not spoken for on this site.
We say so quickly, and — where we can — we point you at investors who are the right fit. That's the more useful thing we can do.
A short deck (10–12 slides) is enough. If we have questions, we write back within a week. If it's a fit, we book time.
A small number of diligence engagements per quarter for boards and co-investors looking at MedTech, SaMD, or diagnostics deals.